Related Experiment Video
Updated: Aug 17, 2026
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors
Filipa Lynce1,2,3, Nancy U Lin1,2
1Division of Breast Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract:
Primary and secondary brain tumors cause significant mortality and constitute an important unmet need. The development of AZD9574, a brain-penetrant, PARP1-selective inhibitor with favorable pharmacologic properties and intriguing preclinical activity, has led to an ongoing clinical trial evaluating it alone and in combination with temozolomide or antibody drug conjugates. See related article by Staniszewska et al., p. 1338.
Insights
AZD9574, a novel brain-penetrant PARP1 inhibitor, shows promise for treating primary and secondary brain tumors. Clinical trials are evaluating its efficacy alone and with other therapies.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Primary and secondary brain tumors represent a significant cause of mortality.
- There is a critical unmet need for effective brain tumor therapies.
- Targeting DNA repair pathways is a promising strategy for cancer treatment.
Purpose of the Study:
- To introduce AZD9574, a selective inhibitor of Poly (ADP-ribose) polymerase 1 (PARP1).
- To highlight the favorable pharmacologic properties and preclinical activity of AZD9574 in brain tumor models.
- To report on the ongoing clinical trial investigating AZD9574 in patients with brain tumors.
Main Methods:
- Development of AZD9574, a brain-penetrant PARP1-selective inhibitor.
- Preclinical studies demonstrating the efficacy of AZD9574.
- Initiation of a clinical trial to evaluate AZD9574 as monotherapy and in combination regimens.
Main Results:
- AZD9574 exhibits desirable pharmacokinetic properties for brain penetration.
- Preclinical data suggest significant anti-tumor activity.
- An ongoing clinical trial is assessing safety and efficacy.
Conclusions:
- AZD9574 is a promising therapeutic candidate for brain tumors.
- Further clinical evaluation is warranted to establish its role in treating primary and secondary brain tumors.
- Combination strategies with temozolomide or antibody drug conjugates are being explored.
